Kikuchi Takashi, Kasai Takatoshi
Makuhari Fuseimyaku Clinic, Chiba 262-0032, Japan.
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan.
World J Cardiol. 2025 May 26;17(5):107434. doi: 10.4330/wjc.v17.i5.107434.
In patients with advanced cancer, the prevalence rate of cardiac autonomic neuropathy (CAN) is high, and the prognosis of patients with CAN is generally poor. Although mechanisms including inflammation, infection, metabolism, neurodegeneration, toxic processes, and cancer treatment have been proposed as etiologies of CAN in cancer patients, these mechanisms have not been completely elucidated, and their relationship has only been described indirectly. A study involving 127 cancer patients revealed that both the disease and its treatments can lead to a decrease in heart rate variability (HRV) indicating the autonomic imbalance. Because managing CAN is essential for improving the survival and quality of life of patients with cancer, patients and specialists can work together to customize cancer treatment and management using HRV as an index.
在晚期癌症患者中，心脏自主神经病变（CAN）的患病率很高，且CAN患者的预后通常较差。尽管包括炎症、感染、代谢、神经退行性变、毒性过程和癌症治疗等机制已被提出作为癌症患者CAN的病因，但这些机制尚未完全阐明，它们之间的关系也只是间接描述。一项涉及127名癌症患者的研究表明，疾病及其治疗均可导致心率变异性（HRV）降低，提示自主神经失衡。由于管理CAN对于提高癌症患者的生存率和生活质量至关重要，患者和专家可以共同努力，以HRV为指标定制癌症治疗和管理方案。
